Kidney cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• MET 2
• CTNNB1 0
• MAPK 0
• PPAR 0
• B7-H3 2
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• IL-6 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  NCT04901702· St. Jude Children's Research Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 35
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 94
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 11
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 60
• Machine Learning 70
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Prognostic role of preoperative low density to non-low-density lipoprotein cholesterol ratio in clear cell renal cell carcinoma: A retrospective study.

  Cancer Causes Control, Nov 2026

• Pre-treatment machine learning prediction of local failure and time to local failure after Gamma Knife radiosurgery for radioresistant brain metastases.

  J Neurooncol, Nov 2026

• Identification and validation of a chronic kidney disease prediction model after radical nephrectomy: a multicenter cohort retrospective study.

  Ann Med, Sept 2026

• Machine learning and multi-omics clustering to map cellular rewiring and immune evasion in ccRCC.

  Hum Genomics, Sept 2026

• A cfDNA fragmentomics classifier for noninvasive differentiation of benign and malignant renal masses.

  Mol Biomed, Sept 2026

• Dual-Matrix Platform for Highly Specific Multi-Omics Profiling of Renal Cell Carcinoma.

  Anal Chem, Sept 2026

• Performance of Machine Learning Models Based on Medical Imaging in Predicting Pathological Grade of Clear Cell Renal Cell Carcinoma.

  Cancer Med, Sept 2026

• Near-infrared spectroscopy for urine-based cancer detection: a systematic characterization of the analytical challenges of a complex biofluid matrix.

  Spectrochim Acta A Mol Biomol Spectrosc, Aug 2026

• Machine learning of sunitinib resistance genes reveals that SP5 regulates angiogenesis and sunitinib resistance in RCC via the VEGFA/AKT axis.

  Neoplasia, Aug 2026

• Integrating single-cell analysis and machine learning algorithms to explore lactylation-related molecular mechanisms and therapeutic responses in clear cell renal cell carcinoma and identifying CDT1 as a potential biomarker.

  Front Endocrinol (Lausanne), Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.